XML 13 R4.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Consolidated Statements Of Operations (USD $)
In Thousands, except Share data
 3 Months Ended 6 Months Ended 116 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Costs and expenses:          
Research and development $ 497 $ 700 $ 1,187 $ 1,520 $ 40,457
Selling, general and administrative 1,207 1,569 2,719 3,197 37,029
Merger transaction costs         5,470
Restructuring expense, net         2,413
Loss on impairment of in-process research and development         6,000
Total costs and expenses 1,704 2,269 3,906 4,717 91,369
Loss from operations (1,704) (2,269) (3,906) (4,717) (91,369)
Gain on bargain purchase         25,282
Gain on assignment of patent rights 2,000   2,000   2,000
Interest and other income   1 1 2 2,025
Interest and other expense (2) (2) (7) (4) (441)
Income (loss) before income taxes 294 (2,270) (1,912) (4,719) (62,503)
Benefit from income taxes         2,281
Net income (loss) 294 (2,270) (1,912) (4,719) (60,222)
Less: Accretion of redeemable convertible preferred stock         (245)
Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions         (781)
Net income (loss) available to common stockholders $ 294 $ (2,270) $ (1,912) $ (4,719) $ (61,248)
Net loss available to common stockholders per share:          
Basic $ 0.03 $ (0.26) $ (0.20) $ (0.58)  
Diluted $ 0.03 $ (0.26) $ (0.20) $ (0.58)  
Weighted average shares outstanding:          
Basic 10,129,328 8,732,837 9,477,206 8,189,663  
Diluted 10,250,178 8,732,837 9,477,206 8,189,663